{
    "clinical_study": {
        "@rank": "48625", 
        "acronym": "OTT 12-06", 
        "arm_group": [
            {
                "arm_group_label": "Vitamin D3", 
                "arm_group_type": "Experimental", 
                "description": "Vitamin D3 40,000 iu per day by mouth"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo taken daily by mouth"
            }
        ], 
        "brief_summary": {
            "textblock": "This protocol is a randomized, phase 2 \"window of opportunity\" trial assessing the\n      biological effects of short term oral vitamin D administration on breast cancer clinical and\n      translational markers in patients awaiting surgery at the Ottawa Hospital. It takes\n      advantage of the current wait times (2-8 weeks) for breast cancer surgery as a \"window of\n      opportunity\" to rapidly assess biological changes with vitamin D intake."
        }, 
        "brief_title": "Effects of Vitamin D in Patients With Breast Cancer", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed female primary breast cancer patients whose surgery is\n             planned for the next 2-8 weeks without neoadjuvant therapy as assessed by\n             multidisciplinary team\n\n          2. Age \u226518 years\n\n          3. Clinically palpable tumour(s) (greater than or equal to 2 cm)\n\n          4. Normal serum and urine calcium and serum PTH values at baseline (as defined by Ottawa\n             Hospital)\n\n          5. Written informed consent for study\n\n        Exclusion Criteria:\n\n          1. Patients with recurrent or metastatic breast cancer\n\n          2. History of neoadjuvant hormonal therapy, chemotherapy, or radiation therapy in the\n             last 6 months for their breast cancer or any other cancer treatment\n\n          3. ECOG performance Status > 2\n\n          4. Hypercalciuria on initial baseline urine, defined as Ca/Creatinine  Ratio> 1.0\n\n          5. Current or previous history of urolithiasis or hyperparathyroidism\n\n          6. Abnormal hepatic function according to Ottawa Hospital norms (Total Bilirubin >2x\n             upper limit of normal, ALT/AST >3x upper limit of normal)and/or abnormal renal\n             function (Creatinine > 150 \u00b5mol/L)\n\n          7. History of granulomatous disease such  as tuberculosis  or sarcoidosis.\n\n          8. Intake of Vitamin D (cholecalciferol) supplement \u2265 2000 IU/day within the last 2\n             months\n\n          9. Inability to comply with a study protocol in the opinion of the investigator (such as\n             abuse of alcohol, drugs or psychotic states)."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "76", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01948128", 
            "org_study_id": "20120362-2OH"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vitamin D3", 
                "description": "Participants will take 4 capsules of Vitamin D which equals 40,000 IU by mouth daily during the wait time between diagnosis and surgery.", 
                "intervention_name": "Vitamin D3", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Vitamin D", 
                    "cholecalciferol"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Participants will take 4 capsules of placebo by mouth daily during the wait time between diagnosis and surgery.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Breast", 
        "lastchanged_date": "January 10, 2014", 
        "location": {
            "contact": {
                "last_name": "Angel Arnaout, Dr.", 
                "phone": "613-798-5555"
            }, 
            "facility": {
                "address": {
                    "city": "Ottawa", 
                    "country": "Canada", 
                    "state": "Ontario"
                }, 
                "name": "The Ottawa Hospital Woman's Breast Health Centre"
            }, 
            "investigator": {
                "last_name": "Angel Arnaout, Dr.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2 Randomized, Double-blind, Window of Opportunity Trial Evaluating Clinical and Correlative Effects of Vitamin D in Patients With Breast Cancer. The ICARUS Trial", 
        "overall_contact": {
            "email": "anarnaout@toh.on.ca", 
            "last_name": "Angel Arnaout, Dr.", 
            "phone": "613-798-5555", 
            "phone_ext": "79071"
        }, 
        "overall_official": {
            "affiliation": "The Ottawa Hospital", 
            "last_name": "Angel Arnaout, Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "Canada: Ethics Review Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Participants will have Ki67 and Caspase 3 levels performed on the tissue that was used to initially diagnose breast cancer. Those levels will then be compared to the tissue acquired at the time of surgery which will occur 2-8 weeks from diagnosis.", 
            "measure": "Pre and post vitamin D administration Ki67 levels and Caspase 3 levels (as assessed according to the apoptosis assay)", 
            "safety_issue": "No", 
            "time_frame": "baseline and 2-8 weeks from baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01948128"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Participant will have Serum levels of 25-0HD and in vivo breast cancer tissue levels of 1,25(OH) taken at baseline and surgery", 
            "measure": "Serum levels of 25-0HD and in vivo breast (cancer and non cancer) tissue levels of 1,25(OH)", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 2-8 weeks from baseline at the time of surgery"
        }, 
        "source": "Ottawa Hospital Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Canadian Breast Cancer Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Ottawa Hospital Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}